aflibercept (Eylea)
Jump to navigation
Jump to search
Indications
- treatment of wet age-related macular degeneration
- visual impairment caused by macular edema secondary to central retinal vein occlusion [NGC (NICE)]
- may be most effective VEGF inhibitor in patients with worst baseline vision[2]
- treatment of diabetic retinopathy[3]
Contraindications
- may not be useful for non-proliferative diabetic retinopathy*
* see clinical trials below
Dosage
solution for injection
Mechanism of action
- recombinant fusion protein consisting of portions of human VEGF receptor 1 & VEGF receptor 2 extracellular domains fused to the Fc portion of human IgG1
- acts as a soluble decoy receptor that binds VEGF-A & PlGF
Clinical trials
- Protocol W Randomized Trial
- 328 adults (399 eyes) 4 year study
- moderate to severe non-proliferative diabetic retinopathy
- initiating intravitreous aflibercept 2.0 mg when vision-threatening complications developed, resulted in statistically significant anatomic improvement but no improvement in visual acuity[4]
More general terms
More specific terms
References
- ↑ FDA NEWS RELEASE: Nov. 18, 2011 FDA approves Eylea for eye disorder in older people http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280601.htm
- ↑ 2.0 2.1 The Diabetic Retinopathy Clinical Research Network. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25692915 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1414264
Martin DF, Maguire MG. Treatment Choice for Diabetic Macular Edema. N Engl J Med. 2015 Feb 18. [Epub ahead of print] <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/25692914 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMe1500351 - ↑ 3.0 3.1 FDA News Release. March 25, 2015 FDA approves new treatment for diabetic retinopathy in patients with diabetic macular edema. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm439838.htm
- ↑ 4.0 4.1 Maturi RK, Glassman AR, Josic K et al Four-Year Visual Outcomes in the Protocol W Randomized Trial of Intravitreous Aflibercept for Prevention of Vision-Threatening Complications of Diabetic Retinopathy. JAMA. 2023;329(5):376-385 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36749332 https://jamanetwork.com/journals/jama/fullarticle/2801058
- ↑ aflibercept (Eylea) prescribing information http://www.regeneron.com/docs/eylea-fpi.pdf